Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.28
-4.3%
$4.67
$3.42
$7.20
$296.81M1.941.54 million shs640,509 shs
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$2.14
+0.9%
$1.89
$0.77
$4.08
$295.93M1.4923,209 shs411,152 shs
2seventy bio, Inc. stock logo
TSVT
2seventy bio
$5.00
$4.98
$2.29
$5.30
$266.15M1.04637,353 shsN/A
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
$2.52
-1.2%
$2.31
$1.90
$4.21
$72.73M0.67171,544 shs92,202 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%+0.55%+18.97%+8.24%-10.53%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
+0.95%+0.95%+15.22%-26.90%+44.22%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
0.00%0.00%+0.20%+89.39%+18.48%
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
+0.79%+4.94%+11.35%-5.56%-35.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.6791 of 5 stars
0.02.00.00.03.40.80.6
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
4.0434 of 5 stars
4.63.00.00.03.45.00.0
2seventy bio, Inc. stock logo
TSVT
2seventy bio
1.2498 of 5 stars
0.94.00.00.02.22.51.3
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
1.3212 of 5 stars
0.03.00.00.02.71.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.11
Buy$13.13513.32% Upside
2seventy bio, Inc. stock logo
TSVT
2seventy bio
1.80
Reduce$4.25-15.00% Downside
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest VTGN, ACB, CMPX, and TSVT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/10/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
5/9/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
4/28/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/24/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
4/22/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/8/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
4/4/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $24.00
4/2/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/2/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $6.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.93$0.20 per share26.35$8.18 per share0.65
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$850K348.15N/AN/A$1.17 per share1.83
2seventy bio, Inc. stock logo
TSVT
2seventy bio
$48.37M5.50N/AN/A$5.04 per share0.99
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
$698K104.20N/AN/A$2.81 per share0.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.05105.6212.00N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$42.49M-$0.41N/AN/AN/AN/A-32.37%-30.67%8/11/2025 (Estimated)
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$217.57M-$0.10N/AN/AN/A-207.25%-53.65%-23.67%8/6/2025 (Estimated)
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
-$29.36M-$1.48N/AN/AN/A-6,777.08%-48.12%-43.80%6/10/2025 (Estimated)

Latest VTGN, ACB, CMPX, and TSVT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/19/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11N/AN/AN/A$88.85 millionN/A
6/10/2025Q4 2025
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
-$0.53N/AN/AN/A$0.18 millionN/A
5/8/2025Q1 2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.12-$0.12N/A-$0.12N/AN/A
5/7/2025Q1 2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$0.10$0.01+$0.11$0.01$13.96 million$22.94 million
3/25/2025Q4 2024
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$0.23-$0.31-$0.08-$0.37$12.84 million$2.93 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/AN/AN/AN/AN/A
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/AN/AN/AN/AN/A
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/A
31.84
31.84
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/A
4.95
4.95
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
N/A
9.35
9.35

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
68.43%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
93.90%
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
78.39%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
29.80%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
7.20%
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
1.29%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
20138.28 million98.38 millionNot Optionable
2seventy bio, Inc. stock logo
TSVT
2seventy bio
44053.23 million47.87 millionOptionable
Vistagen Therapeutics, Inc. stock logo
VTGN
Vistagen Therapeutics
4028.86 million28.49 millionOptionable

Recent News About These Companies

VistaGen’s Earnings Call: Progress and Challenges
Vistagen reports Q3 EPS (46c) vs (22c) last year

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.28 -0.24 (-4.35%)
Closing price 04:00 PM Eastern
Extended Trading
$5.31 +0.03 (+0.57%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Compass Therapeutics stock logo

Compass Therapeutics NASDAQ:CMPX

$2.14 +0.02 (+0.94%)
Closing price 04:00 PM Eastern
Extended Trading
$2.12 -0.02 (-0.93%)
As of 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

2seventy bio stock logo

2seventy bio NASDAQ:TSVT

$5.00 0.00 (0.00%)
As of 05/13/2025

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Vistagen Therapeutics stock logo

Vistagen Therapeutics NASDAQ:VTGN

$2.52 -0.03 (-1.18%)
Closing price 04:00 PM Eastern
Extended Trading
$2.58 +0.06 (+2.18%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.